Related Experiment Video
Updated: Jan 20, 2026

Force and Position Control in Humans - The Role of Augmented Feedback
Published on: June 19, 2016
KRASG12/13 mutation modulates CRC outcomes via disrupting positive feedback between macrophage and CD4+ T cell
Xuehan Yan1, Juncheng Su1, Hongyuan Liu2
1Department of Gastrointestinal Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Abstract:
Kirsten rat sarcoma viral oncogene (KRAS) mutation influences colorectal cancer (CRC) progression, but their specific impact on the tumor immune microenvironment remains poorly defined. This study establishes that KRASG12/13 mutation disrupts critical positive feedback between macrophages and CD4+ T cells. Mechanistically, KRASG12/13-mutant tumor cells secrete elevated interleukin-10 (IL-10), which suppresses macrophage production of chemokine ligand 9/10 (CXCL9/10) and major histocompatibility complex II (MHC-II). This impairs the infiltration and activation of CXCR3+CD4+ T cells, fostering an immunosuppressive niche. By integrating multi-omics data from clinical cohorts and validating findings in vivo, we show that combining KRAS inhibitors with CXCL9/10 restoration effectively overcomes this immune suppression and controls tumor growth. Our work delineates a targetable immune evasion mechanism and provides a cohesive prognostic and therapeutic framework for KRASG12/13-mutant CRC.
Insights
KRAS mutations in colorectal cancer disrupt immune cell interactions. Restoring CXCL9/10 with KRAS inhibitors overcomes immune suppression and controls tumor growth.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Kirsten rat sarcoma viral oncogene (KRAS) mutations are key drivers in colorectal cancer (CRC) progression.
- The precise influence of KRAS mutations on the tumor immune microenvironment (TIME) is not fully understood.
Purpose of the Study:
- To elucidate the impact of KRASG12/13 mutations on the TIME in colorectal cancer.
- To identify mechanisms of immune evasion driven by KRAS mutations.
- To propose novel therapeutic strategies for KRASG12/13-mutant CRC.
Main Methods:
- Integration of multi-omics data from clinical CRC cohorts.
- In vivo validation of identified mechanisms.
- Analysis of immune cell interactions, cytokine profiles, and chemokine expression.
Main Results:
- KRASG12/13 mutations disrupt the positive feedback loop between macrophages and CD4+ T cells.
- Mutant tumor cells secrete increased interleukin-10 (IL-10), suppressing macrophage production of CXCL9/10 and MHC-II.
- Impaired infiltration and activation of CXCR3+CD4+ T cells create an immunosuppressive tumor microenvironment.
Conclusions:
- KRASG12/13 mutation drives immune evasion in CRC through IL-10-mediated suppression of macrophage chemokine and MHC-II expression.
- Restoring CXCL9/10 levels in combination with KRAS inhibition offers a promising therapeutic approach.
- This study provides a framework for targeting immune evasion in KRASG12/13-mutant colorectal cancer.
More Related Videos
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
06:59Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022
Related Concept Videos
Positive and Negative Feedback Loops
06:31Force and Position Control in Humans - The Role of Augmented Feedback
Root Loci for Positive-Feedback Systems
The construction rules for the root locus in positive feedback systems are similar to those in...
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
06:59Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
04:51High-Efficiency Gene Disruption in Primary Bone Marrow-Derived Macrophages Using Electroporated Cas9-sgRNA Complexes